Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.76 |
| ▸ | DHODH | Q02127 | 5/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | TACR3 | P29371 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.60 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10757465 | 0.98 | KDM4E (0.73) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL4461764 | 0.91 | DHODH (0.74) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL10867811 | 0.90 | DHODH (0.62) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Hydrochloric Acid SCHEMBL4463065 | 0.90 | DHODH (0.72) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL10865568 | 0.90 | DHODH (0.62) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL19508769 | 0.90 | DHODH (0.62) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL6209856 | 0.87 | KDM4E (0.76) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| SCHEMBL13957862 | 0.86 | LMNA (0.57) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Cinchophen SCHEMBL7588217 | 0.86 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10ADHODH | |
| Cinchophen SCHEMBL25519 | 0.86 | KDM4E (1.00) | KDM4ELMNASMN1; SMN2PDE10ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| CN-101287723-A | Amidoalkylpyridylquinolines as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | CN | claimed |
| CN-101282964-A | Oxopyridyl quinoline amides as NK3 receptor modulators | ASTRAZENECA AB (SE) | 2008-10-08 | — | — | CN | claimed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| EP-1915363-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| WO-2007018469-A1 | OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| CN-105102442-B | Quinoline as anticarcinogen | 基因科学医药公司 | 2018-11-09 | — | — | CN | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2325181-B1 | STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT | GENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| CN-103965107-B | 2-aryl substituted quinoline derivatives and application thereof | 沈阳药科大学 | 2016-08-17 | — | — | CN | disclosed |
| CN-1156451-A | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 1997-08-06 | — | — | CN | disclosed |
| WO-1997019927-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| WO-1996002509-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1996-02-01 | — | — | WO | disclosed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
| US-4711890-A | TREATMENT OF ANXIETY STATES OR OF PULMONARY, RENAL, CIRCULATORY OF CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-12-08 | — | — | US | disclosed |
| US-4684652-A | TREATING ANXIETY OR CARDIOVASCULAR DISORDERS | RHONE-POULENC SANTE (FR) | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | KDM4E 979/4885LMNA 2412/4885SMN1; SMN2 3931/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | KDM4E 979/4885LMNA 2412/4885SMN1; SMN2 3931/4885 |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | KDM4E 1246/4885LMNA 3842/4885SMN1; SMN2 4419/4885 |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | NPY4R, PROKR1, NPSR1 | KDM4E 1906/4885LMNA 2776/4885SMN1; SMN2 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.